Clinical Trial News and Research

RSS

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

23 Apr 2013

AfriCoLeish receives grant from European Union to test new treatments for kala-azar

Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of -3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.

23 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

Study: Atrophy in an important area of brain predicts multiple sclerosis

Magnetic resonance imaging (MRI) measurements of atrophy in an important area of the brain are an accurate predictor of multiple sclerosis (MS), according to a new study published online in the journal Radiology.

23 Apr 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

23 Apr 2013

White button mushrooms can help maintain weight loss, say researchers

New research published as an abstract in The FASEB Journal and presented at Experimental Biology 2013 (EB 2013) on Monday, April 22 ties mushrooms to positive health outcomes in the area of weight management.

23 Apr 2013

BAROnova presents ENDObesity I clinical trial data at SAGES meeting

BAROnova, Inc., recently presented data from their ENDObesity I clinical trial at the annual Society of American Gastrointestinal and Endoscopic Surgeons meeting.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

Researchers find innovative approach to treat lazy eye disorder

A research team led by Dr. Robert Hess from McGill University and the Research Institute of the McGill University Health Centre has used the popular puzzle video game Tetris in an innovative approach to treat adult amblyopia, commonly known as "lazy eye".

23 Apr 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

Pergamum reaches LPLV in Phase I/II trial of LL-37 for treatment of hard-to-heal venous leg ulcers

Pergamum AB announced today that the company has reached last-patient-last-visit in a randomized Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of Pergamum.

23 Apr 2013

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Two large, landmark radiotherapy studies have shown that it is possible to treat cervical cancer effectively with high doses specifically adapted to each tumour, and with fewer serious side-effects to the surrounding normal organs.

22 Apr 2013

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.

22 Apr 2013

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions and services provider in a new phase II clinical trial on Non Small Cell Lung Cancer (NSCLC).

22 Apr 2013

DecImmune and DSM to develop proprietary antibody therapeutic

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.

22 Apr 2013

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

20 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013

Clinical Trial News and Research

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

AfriCoLeish receives grant from European Union to test new treatments for kala-azar

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Study: Atrophy in an important area of brain predicts multiple sclerosis

Unavoidable damage to heart and lungs can be limited by using CVD drug

White button mushrooms can help maintain weight loss, say researchers

BAROnova presents ENDObesity I clinical trial data at SAGES meeting

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

Researchers find innovative approach to treat lazy eye disorder

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

Pergamum reaches LPLV in Phase I/II trial of LL-37 for treatment of hard-to-heal venous leg ulcers

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

DecImmune and DSM to develop proprietary antibody therapeutic

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery